Voyager Therapeutics Email Format

Biotechnology Research
51-200 employees
Lexington, MA, USA

Voyager Therapeutics is a biotechnology company leveraging human genetics to develop treatments and potential cures for neurological diseases including Alzheimer's, Parkinson's, and ALS.

Find contacts at Voyager Therapeutics

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

firstinitiallast@vygr.com

Company Overview

Industry
Biotechnology Research
Founded
2014
Headquarters
Lexington, MA, USA
Revenue
$100M+
FUNDING Stage
Public
Key Executives
Alfred W. Sandrock, Jr., M.D., Ph.D. (President and Chief Executive Officer), Robin Swartz (Principal Financial Officer, Chief Operating Officer and Chief Business Officer), Robin Swartz (Chief Business Officer and Chief Operating Officer)

Tech Stack

Veeva Vault

CMS

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Voyager Therapeutics?

Voyager Therapeutics uses the firstinitiallast format, so Jane Smith would be jsmith@vygr.com.

What neurological diseases does Voyager Therapeutics target with its gene therapy pipeline?

Voyager Therapeutics is developing genetic medicines targeting Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, and ALS, among other central nervous system diseases. Its pipeline includes both wholly owned programs and programs partnered with companies like Neurocrine Biosciences.

How does Voyager Therapeutics use its TRACER capsid platform to advance gene therapy?

The TRACER platform is an RNA-based screening system that allows Voyager Therapeutics to rapidly discover novel AAV capsids for targeted gene delivery to specific cell types in the brain, and it underpins multiple partnered programs with Neurocrine Biosciences, Novartis, and Alexion.

Who leads Voyager Therapeutics as CEO in 2026?

Alfred W. Sandrock, Jr., M.D., Ph.D. serves as President and Chief Executive Officer of Voyager Therapeutics. Robin Swartz serves as Chief Operating Officer, Chief Business Officer, and Principal Financial Officer.

Can Clay help me find and verify contact details for researchers or business development leads at Voyager Therapeutics?

Yes, Clay can enrich a prospecting list with verified contact information for Voyager Therapeutics employees, including emails following the firstinitiallast@vygr.com format, making it easier to reach the right science or business development contacts at the company.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles